Alexium International Group（E7T）株式概要アレクシウム・インターナショナル・グループ・リミテッドは、相変化材料（PCM）やその他の特殊繊維ソリューションを米国で製造・販売している。 詳細E7T ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ German市場と比較して、過去 3 か月間の株価の変動が非常に大きいマイナスの株主資本 過去5年間で収益は年間9.2%減少しました。 +2 さらなるリスクすべてのリスクチェックを見るE7T Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.000523.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-11m16m2016201920222025202620282031Revenue US$1.7mEarnings US$161.4kAdvancedSet Fair ValueView all narrativesAlexium International Group Limited 競合他社Bio-GateSymbol: DB:BIG1Market cap: €7.2mLANXESSSymbol: XTRA:LXSMarket cap: €1.5bDelignitSymbol: XTRA:DLXMarket cap: €26.6mEcoRubSymbol: DB:7M8Market cap: €40.2m価格と性能株価の高値、安値、推移の概要Alexium International Group過去の株価現在の株価AU$0.000552週高値AU$0.00852週安値AU$0.0005ベータ0.621ヶ月の変化0%3ヶ月変化0%1年変化0%3年間の変化-93.75%5年間の変化-98.21%IPOからの変化-99.58%最新ニュースBoard Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 16Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group.Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group on December 15, 2025. The consideration consists of common equity of Alexium International Group Limited to be issued for common equity of Microtek Laboratories, Inc. Alexium International Group Limited (ASX:AJX) completed the acquisition of Microtek Laboratories, Inc. from CAVU Group on December 15, 2025.お知らせ • Dec 15Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million.Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,127,664,547 Price\Range: AUD 0.006 Transaction Features: Rights Offeringお知らせ • Oct 22Alexium International Group Limited, Annual General Meeting, Nov 21, 2025Alexium International Group Limited, Annual General Meeting, Nov 21, 2025. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000 Australiaお知らせ • Aug 04Alexium International Group Limited Announces Resignation of Bob Brookins as Chief Technology Officer and Executive Director, Effective August 4, 2025Alexium International Group Limited announces that the Company's Chief Technology Officer and Executive Director, Dr Bob Brookins, has given notice of his intention to resign his roles after over 10 years of service. After completion of his three months notice period, Dr Brookins will become a consultant to the Company supporting Alexium's Technical Team which will now be led by Mr. Nick Leitner. Dr Brookins's resignation from Alexium's Board of Directors will be effective from August 4.お知らせ • Oct 18Alexium International Group Limited, Annual General Meeting, Nov 20, 2024Alexium International Group Limited, Annual General Meeting, Nov 20, 2024. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000. Australia最新情報をもっと見るRecent updatesBoard Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 16Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group.Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group on December 15, 2025. The consideration consists of common equity of Alexium International Group Limited to be issued for common equity of Microtek Laboratories, Inc. Alexium International Group Limited (ASX:AJX) completed the acquisition of Microtek Laboratories, Inc. from CAVU Group on December 15, 2025.お知らせ • Dec 15Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million.Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,127,664,547 Price\Range: AUD 0.006 Transaction Features: Rights Offeringお知らせ • Oct 22Alexium International Group Limited, Annual General Meeting, Nov 21, 2025Alexium International Group Limited, Annual General Meeting, Nov 21, 2025. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000 Australiaお知らせ • Aug 04Alexium International Group Limited Announces Resignation of Bob Brookins as Chief Technology Officer and Executive Director, Effective August 4, 2025Alexium International Group Limited announces that the Company's Chief Technology Officer and Executive Director, Dr Bob Brookins, has given notice of his intention to resign his roles after over 10 years of service. After completion of his three months notice period, Dr Brookins will become a consultant to the Company supporting Alexium's Technical Team which will now be led by Mr. Nick Leitner. Dr Brookins's resignation from Alexium's Board of Directors will be effective from August 4.お知らせ • Oct 18Alexium International Group Limited, Annual General Meeting, Nov 20, 2024Alexium International Group Limited, Annual General Meeting, Nov 20, 2024. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000. AustraliaReported Earnings • Aug 30Full year 2024 earnings releasedFull year 2024 results: Revenue: US$5.89m (down 18% from FY 2023). Net loss: US$2.76m (loss narrowed 6.4% from FY 2023).New Risk • Aug 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.58m (US$8.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (140% increase in shares outstanding). Market cap is less than US$10m (€7.58m market cap, or US$8.36m).Board Change • Jul 11Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Carl Dennis was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • May 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 139% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€11.5m market cap, or US$12.4m).New Risk • May 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 47% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-US$3.1m). Market cap is less than US$10m (€6.44m market cap, or US$6.92m). Minor Risk Shareholders have been diluted in the past year (47% increase in shares outstanding).Reported Earnings • Feb 29First half 2024 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1H 2023)First half 2024 results: US$0.003 loss per share (improved from US$0.004 loss in 1H 2023). Revenue: US$2.77m (down 20% from 1H 2023). Net loss: US$1.96m (loss narrowed 17% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.お知らせ • Dec 27+ 1 more updateAlexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 38,461,538 Price\Range: AUD 0.013 Transaction Features: Subsequent Direct ListingNew Risk • Dec 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.5m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-US$983k). Market cap is less than US$10m (€6.11m market cap, or US$6.71m). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding).お知らせ • Oct 26Alexium International Group Limited Announces Resignation of Stephen Cheney as Non-Executive Director, Effective 1 November 2023Alexium International Group Limited announced that Brigadier General Stephen Cheney, USMC (Ret) has advised the Company of his intention to resign as Non-Executive Director of Alexium, effective 1 November 2023. Mr. Cheney has been a Non-Executive Director of Alexium since April 2015 and has served on the Company's Audit, Nomination & Remuneration, and Risk Committees.New Risk • Oct 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.5m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-US$983k). Market cap is less than US$10m (€7.94m market cap, or US$8.42m). Minor Risk Shareholders have been diluted in the past year (2.0% increase in shares outstanding).お知らせ • Sep 27Alexium International Group Limited, Annual General Meeting, Nov 15, 2023Alexium International Group Limited, Annual General Meeting, Nov 15, 2023, at 10:30 AUS Eastern Standard Time. Location: offices of Grant Thornton, Level 17, 383 Kent Street, 2000 Sydney New South Wales Australia Agenda: To consider the election of director.Reported Earnings • Aug 25Full year 2023 earnings released: US$0.005 loss per share (vs US$0.005 loss in FY 2022)Full year 2023 results: US$0.005 loss per share (in line with FY 2022). Revenue: US$7.21m (down 12% from FY 2022). Net loss: US$2.95m (loss narrowed 12% from FY 2022). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 26First half 2023 earnings releasedFirst half 2023 results: Revenue: US$3.44m (down 35% from 1H 2022). Net loss: US$2.37m (loss widened 22% from 1H 2022).Board Change • Nov 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 26Full year 2022 earnings released: US$0.005 loss per share (vs US$0.002 loss in FY 2021)Full year 2022 results: US$0.005 loss per share (down from US$0.002 loss in FY 2021). Revenue: US$8.17m (up 12% from FY 2021). Net loss: US$3.36m (loss widened 133% from FY 2021). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 01First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: US$0.003 loss per share (vs US$0.003 loss in 1H 2021). Revenue: US$5.28m (up 46% from 1H 2021). Net loss: US$1.95m (loss widened 8.9% from 1H 2021). Revenue exceeded analyst estimates by 176%. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 28Full year 2021 earnings released: US$0.002 loss per share (vs US$0.013 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: US$7.28m (up 20% from FY 2020). Net loss: US$1.45m (loss narrowed 76% from FY 2020). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 26First half 2021 earnings released: US$0.003 loss per share (vs US$0.012 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: US$3.61m (up 14% from 1H 2020). Net loss: US$1.79m (loss narrowed 59% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.株主還元E7TDE ChemicalsDE 市場7D0%-0.3%3.2%1Y0%5.7%2.5%株主還元を見る業界別リターン: E7T過去 1 年間で5.7 % の収益を上げたGerman Chemicals業界を下回りました。リターン対市場: E7Tは、過去 1 年間で2.5 % のリターンをもたらしたGermanマーケットと一致しました。価格変動Is E7T's price volatile compared to industry and market?E7T volatilityE7T Average Weekly Movement731.3%Chemicals Industry Average Movement6.0%Market Average Movement6.1%10% most volatile stocks in DE Market13.6%10% least volatile stocks in DE Market2.7%安定した株価: E7Tの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: E7Tの 週次ボラティリティ は、過去 1 年間で373%から731%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aBilly Blackburnwww.alexiuminternational.comアレクシウム・インターナショナル・グループ・リミテッドは、相変化材料（PCM）やその他の特殊繊維ソリューションを米国で製造・販売している。アレクシクール（Alexicool）PCM仕上げ加工、バイオクール（Biocool）天然・バイオベースのマイクロカプセル化PCM冷却、エクリプシス（Eclipsys）永久冷却技術などの熱調整ソリューションを提供している。また、軍用繊維向け難燃加工アレキシフラム、熱管理製品デルクール、アレキシガード補助加工などの難燃性ソリューションも提供している。同社は寝具、防護服、軍服、作業着市場、繊維および発泡体市場に製品を供給している。本拠地はサウスカロライナ州グリア。もっと見るAlexium International Group Limited 基礎のまとめAlexium International Group の収益と売上を時価総額と比較するとどうか。E7T 基礎統計学時価総額€13.45m収益（TTM）-€3.76m売上高(TTM)€2.95m4.6xP/Sレシオ-3.6xPER（株価収益率E7T は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計E7T 損益計算書（TTM）収益US$3.42m売上原価US$1.97m売上総利益US$1.46mその他の費用US$5.82m収益-US$4.37m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0014グロス・マージン42.54%純利益率-127.51%有利子負債／自己資本比率-153.1%E7T の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 16:37終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Alexium International Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 16Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group.Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group on December 15, 2025. The consideration consists of common equity of Alexium International Group Limited to be issued for common equity of Microtek Laboratories, Inc. Alexium International Group Limited (ASX:AJX) completed the acquisition of Microtek Laboratories, Inc. from CAVU Group on December 15, 2025.
お知らせ • Dec 15Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million.Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,127,664,547 Price\Range: AUD 0.006 Transaction Features: Rights Offering
お知らせ • Oct 22Alexium International Group Limited, Annual General Meeting, Nov 21, 2025Alexium International Group Limited, Annual General Meeting, Nov 21, 2025. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000 Australia
お知らせ • Aug 04Alexium International Group Limited Announces Resignation of Bob Brookins as Chief Technology Officer and Executive Director, Effective August 4, 2025Alexium International Group Limited announces that the Company's Chief Technology Officer and Executive Director, Dr Bob Brookins, has given notice of his intention to resign his roles after over 10 years of service. After completion of his three months notice period, Dr Brookins will become a consultant to the Company supporting Alexium's Technical Team which will now be led by Mr. Nick Leitner. Dr Brookins's resignation from Alexium's Board of Directors will be effective from August 4.
お知らせ • Oct 18Alexium International Group Limited, Annual General Meeting, Nov 20, 2024Alexium International Group Limited, Annual General Meeting, Nov 20, 2024. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000. Australia
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 16Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group.Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group on December 15, 2025. The consideration consists of common equity of Alexium International Group Limited to be issued for common equity of Microtek Laboratories, Inc. Alexium International Group Limited (ASX:AJX) completed the acquisition of Microtek Laboratories, Inc. from CAVU Group on December 15, 2025.
お知らせ • Dec 15Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million.Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,127,664,547 Price\Range: AUD 0.006 Transaction Features: Rights Offering
お知らせ • Oct 22Alexium International Group Limited, Annual General Meeting, Nov 21, 2025Alexium International Group Limited, Annual General Meeting, Nov 21, 2025. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000 Australia
お知らせ • Aug 04Alexium International Group Limited Announces Resignation of Bob Brookins as Chief Technology Officer and Executive Director, Effective August 4, 2025Alexium International Group Limited announces that the Company's Chief Technology Officer and Executive Director, Dr Bob Brookins, has given notice of his intention to resign his roles after over 10 years of service. After completion of his three months notice period, Dr Brookins will become a consultant to the Company supporting Alexium's Technical Team which will now be led by Mr. Nick Leitner. Dr Brookins's resignation from Alexium's Board of Directors will be effective from August 4.
お知らせ • Oct 18Alexium International Group Limited, Annual General Meeting, Nov 20, 2024Alexium International Group Limited, Annual General Meeting, Nov 20, 2024. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000. Australia
Reported Earnings • Aug 30Full year 2024 earnings releasedFull year 2024 results: Revenue: US$5.89m (down 18% from FY 2023). Net loss: US$2.76m (loss narrowed 6.4% from FY 2023).
New Risk • Aug 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.58m (US$8.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (140% increase in shares outstanding). Market cap is less than US$10m (€7.58m market cap, or US$8.36m).
Board Change • Jul 11Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Carl Dennis was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • May 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 139% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€11.5m market cap, or US$12.4m).
New Risk • May 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 47% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-US$3.1m). Market cap is less than US$10m (€6.44m market cap, or US$6.92m). Minor Risk Shareholders have been diluted in the past year (47% increase in shares outstanding).
Reported Earnings • Feb 29First half 2024 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1H 2023)First half 2024 results: US$0.003 loss per share (improved from US$0.004 loss in 1H 2023). Revenue: US$2.77m (down 20% from 1H 2023). Net loss: US$1.96m (loss narrowed 17% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
お知らせ • Dec 27+ 1 more updateAlexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 38,461,538 Price\Range: AUD 0.013 Transaction Features: Subsequent Direct Listing
New Risk • Dec 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.5m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-US$983k). Market cap is less than US$10m (€6.11m market cap, or US$6.71m). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
お知らせ • Oct 26Alexium International Group Limited Announces Resignation of Stephen Cheney as Non-Executive Director, Effective 1 November 2023Alexium International Group Limited announced that Brigadier General Stephen Cheney, USMC (Ret) has advised the Company of his intention to resign as Non-Executive Director of Alexium, effective 1 November 2023. Mr. Cheney has been a Non-Executive Director of Alexium since April 2015 and has served on the Company's Audit, Nomination & Remuneration, and Risk Committees.
New Risk • Oct 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.5m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-US$983k). Market cap is less than US$10m (€7.94m market cap, or US$8.42m). Minor Risk Shareholders have been diluted in the past year (2.0% increase in shares outstanding).
お知らせ • Sep 27Alexium International Group Limited, Annual General Meeting, Nov 15, 2023Alexium International Group Limited, Annual General Meeting, Nov 15, 2023, at 10:30 AUS Eastern Standard Time. Location: offices of Grant Thornton, Level 17, 383 Kent Street, 2000 Sydney New South Wales Australia Agenda: To consider the election of director.
Reported Earnings • Aug 25Full year 2023 earnings released: US$0.005 loss per share (vs US$0.005 loss in FY 2022)Full year 2023 results: US$0.005 loss per share (in line with FY 2022). Revenue: US$7.21m (down 12% from FY 2022). Net loss: US$2.95m (loss narrowed 12% from FY 2022). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 26First half 2023 earnings releasedFirst half 2023 results: Revenue: US$3.44m (down 35% from 1H 2022). Net loss: US$2.37m (loss widened 22% from 1H 2022).
Board Change • Nov 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 26Full year 2022 earnings released: US$0.005 loss per share (vs US$0.002 loss in FY 2021)Full year 2022 results: US$0.005 loss per share (down from US$0.002 loss in FY 2021). Revenue: US$8.17m (up 12% from FY 2021). Net loss: US$3.36m (loss widened 133% from FY 2021). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 01First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: US$0.003 loss per share (vs US$0.003 loss in 1H 2021). Revenue: US$5.28m (up 46% from 1H 2021). Net loss: US$1.95m (loss widened 8.9% from 1H 2021). Revenue exceeded analyst estimates by 176%. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 28Full year 2021 earnings released: US$0.002 loss per share (vs US$0.013 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: US$7.28m (up 20% from FY 2020). Net loss: US$1.45m (loss narrowed 76% from FY 2020). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 26First half 2021 earnings released: US$0.003 loss per share (vs US$0.012 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: US$3.61m (up 14% from 1H 2020). Net loss: US$1.79m (loss narrowed 59% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.
